Navigation Links
ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
Date:11/11/2010

THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section http://www.bioworld.com/.

The publication noted that, "ImmunGene is currently in advanced partnership discussion with several biotech and pharma companies for its payload... The firm's approach involves fusing a monoclonal antibody with a cytokine, initially interferon, for local delivery to the tumor. Called a CmAb, the molecule can be aimed 'directly where we want it to go,' (CEO Sanjay) Khare said."

The addition of the cytokine means that: "'...our CmAbs can do more [than other antibody arming ADCs] since select cytokines are associated with several desirable anti-tumor functions,' he said. CmAbs also are genetically engineered molecules, which could make them simpler and cheaper to produce. 'There's no multistep manufacturing process,' Khare added."

"Another benefit is that the CmAbs can be dosed at a very low level and still be efficacious. ImmunGene's researchers, for example, have been able to limit interferon activity in CmAb to one-one hundredth of the unfused IFN. By fusing it with an antibody that binds only to tumor cells, that interferon dose is sufficient to initiate cell death. ImmunGene's lead CmAb candidate, IGN002, is a third-generation antibody-fusion drug designed to target CD20-positive tumors, initially going after non-Hodgkin's lymphoma not treatable by Rituxan (rituximab, Genentech Inc./Roche AG and Biogen Idec Inc.)," noted the BioWorld article.

Dr. Sanjay Khare, ImmunGene's Chief Executive Officer said, "We are pleased to receive recognition from a global biotech publication for ImmunGene's pipeline of next genera
'/>"/>

SOURCE ImmunGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
2. Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates
3. Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
4. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
7. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
8. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
9. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
10. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  NeuroSigma, Inc. (NeuroSigma), a California ... non-invasive Monarch ™ eTNS™ Therapy for ... that enrollment has begun in a pediatric open label ... therapy for the treatment of Lennox-Gastaut Syndrome (LGS). ... View-UCLA Medical Center in Sylmar, California ...
(Date:7/22/2014)... England , July 22, 2014 ... development and device company focused on solid dose ... its novel solid formulation of octreotide acetate achieved ... it with the currently marketed liquid product (Sandostatin®). ... transfer the formulation production process to a contract ...
(Date:7/21/2014)... N.J. , July 21, 2014  Champions Oncology ... advanced technology solutions and services to personalize the development ... report its financial and operational results for the fourth ... Thursday, July 24, 2014, after market close. ... the results that day at 4:30 p.m. EDT (1:30 ...
Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... 10, 2011 USANA Health Sciences, Inc. (NYSE: ... nutritional gaps are common in the average American diet and ... those gaps.  However, USANA scientists and advising physicians caution that ... Dietary Guidelines for Americans, 2010 and ...
... MATEO, Calif., Feb. 10, 2011 AlphaDetail, a leader ... biotech industries, reported a 30% increase in revenue in ... time in the company,s history. "Our clients ... provides the marketing research solutions that get at the ...
Cached Medicine Technology:USDA Recognizes Benefit of Supplements in New Dietary Guidelines But Doesn't Go Far Enough 2AlphaDetail Revenue Soars 30% in 2010 2
(Date:7/22/2014)... 2014 Visitors to the Radiometer booth ... July 29-31) will have the opportunity to learn from ... errors. Radiometer will host two sessions of each presentation ... Individualized Quality Control Plan (IQCP) for Blood Gas Testing, ... Sy Albakri, PhD, Clinical and Scientific Affairs Manager, Radiometer ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Recently, 2014quinceaneradresses.com, ... has announced its latest assortment of blue and ... promotional prices on these special Quinceanera gowns, hoping to ... before July 30 can get a discounted price, up ... very glad to announce these new items. As one ...
(Date:7/22/2014)... July 22, 2014 MyDiettogo ... well as community discussion forums, to make it easier ... health. Customers now can track their Diet-to-Go meals, change ... journey, all from their computer or smart phone. Diet-to-Go ... staff Nutritionist and Certified Health Coach. , According to ...
(Date:7/22/2014)... 22, 2014 Industry-leading health business information ... release of Specialty Pharmacy Trends and Strategies: 2014 ... provides a comprehensive overview of the current state of ... strategies and tactics for:, , Specialty ... utilization concerns — including details of coinsurance levels by ...
(Date:7/22/2014)... 22, 2014 To help offset the ... Therapy Training Institute of Miami is reducing the ... award-winning model Brief Strategic Family Therapy™. To implement ... a variety of funding sources, but those opportunities seem ... situation we want to help relieve somehow,” said the ...
Breaking Medicine News(10 mins):Health News:Radiometer Features Booth Presentations On IQCP and Blood Gas Preanalytics at the 2014 AACC Clinical Lab Expo 2Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:Diet-to-Go Introduces New Online and Mobile Weight-Loss Tools, with Apps for iPhone and Android 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 3
... combines bone marrow removal and injection of a hormone ... locations in the body, it was reported by Yale ... "This could radically change the way patients are currently ... traumatic long bone fractures," said senior author Agns ...
... AUBURN HILLS, Mich., Feb. 14 Armed with the ... a hefty price tag, a,major automotive company has taken ... The program is 10 times more effective and ... and is expected to,translate into significant healthcare expense savings., ...
... this problem is an important step before moving on to ... major concern with using stem cells to treat disease has ... cells might cause cancer, but now a group of scientists ... groups of researchers -- one in Japan and one in ...
... Goes to Conference Committee Next Before Final Version is,Voted ... repayment,program for professions of "national need" will include occupational,therapists ... agreed to by the,Senate. AOTA staff worked fast and ... late last week. AOTA was able to have Representative ...
... Eye Care & Dental Professionals Kick off Year-Long Initiative, ... in Buffalo,NY, the world is about to become brighter. ... by volunteers recently at the first of,Davis Vision,s 2008 ... Bills, the event attracted 100 children,ages 5 through 16 ...
... Boston Scientific,Corporation (NYSE: BSX ) today announced that ... Venous Access businesses to Avista Capital,Partners for $425 million ... December 13, 2007., The Company expects to record ... quarter of 2008 in connection with the,transaction., "The ...
Cached Medicine News:Health News:Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 2Health News:Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 3Health News:Scientists Show Stem Cells Don't Cause Cancer 2Health News:Scientists Show Stem Cells Don't Cause Cancer 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 3Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 2Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 3Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 4
... Mumps IgG Enzyme- linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to Mumps virus ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... Ultra Laboratory has been uniquely designed ... single facility to integrated networks spanning ... to management reporting and accounts receivable, ... precise laboratory management. All system modules ...
Medicine Products: